News
News
New Cardiovascular Device Approved in Japan: Elixir Medical Announces Regulatory Approval of DynamX® Coronary Bioadaptor System
Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the DynamX® Coronary Bioadaptor System for the treatment of coronary artery disease, making DynamX® the first and unique coronary implant approved in Japan to restore arterial function known as hemodynamic modulation after percutaneous coronary intervention (PCI) procedure, with demonstrated improved patient survival and reduced re-interventions compared to drug-eluting stents (DES).
EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent in Long-Term Follow-Up, Including Reduction in Cardiovascular Death
Elixir Medical announced four-year results from the large 445-patient BIOADAPTOR Randomized Controlled Trial (RCT), comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent (DES) at 34 centers presented at a late-breaking clinical trial session during EuroPCR 2026.
Elixir Medical Highlights Results From “Real World” MY-IVL Study Demonstrating Performance of LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Treating Calcified Coronary Lesions
Elixir Medical announced results from the MY-IVL Study at the TCT Conference 2025 that demonstrate performance of Lithix™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in treating heart disease.
Elixir Medical Announces Key Commercial Milestone With LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL)
Elixir Medical announces key commercial milestone with LithiX™ HC-IVL, a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaques. New clinical study to be presented at TCT Conference 2025.
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX® Bioadaptor Over Drug-Eluting Stent Through Three Years
Late-breaking data demonstrate sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) and significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with DynamX® compared to DES.
Elixir Medical Announces Launch of LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Europe
Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an energy source. IVL technology expands company’s innovative product portfolio.
Elixir Medical Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
Elixir Medical’s LithiX HC-IVL system data demonstrate sustained safety and efficacy at six months, as reported at the TCT conference.
Elixir Medical’s LithiX HC-IVL System Data Demonstrate Sustained Safety and Efficacy at Six Months
Elixir Medical’s LithiX HC-IVL system data demonstrate sustained safety and efficacy at six months, as reported at the TCT conference.
Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
—Late-breaking 12-month data from INFINITY-SWEDEHEART presented at TCT 2024 further validate bioadaptor’s unique mechanism of action in complex PCI population subsets— —Results of INFINITY-SWEDEHEART trial
PMN 1714 Rev A